본문으로 건너뛰기
← 뒤로

Comment on "Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study".

Hepatology international 2026

Wang H, Xu X, Song X, Zhang Y

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Wang H, Xu X, et al. (2026). Comment on "Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study".. Hepatology international. https://doi.org/10.1007/s12072-025-10970-9
MLA Wang H, et al.. "Comment on "Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study".." Hepatology international, 2026.
PMID 41483107

같은 제1저자의 인용 많은 논문 (5)